keyword
MENU ▼
Read by QxMD icon Read
search

Respiratory Syncytial Virus vaccine

keyword
https://www.readbyqxmd.com/read/27914740/predicting-the-relative-impacts-of-maternal-and-neonatal-respiratory-syncytial-virus-rsv-vaccine-target-product-profiles-a-consensus-modelling-approach
#1
Wirichada Pan-Ngum, Timothy Kinyanjui, Moses Kiti, Sylvia Taylor, Jean-François Toussaint, Sompob Saralamba, Thierry Van Effelterre, D James Nokes, Lisa J White
BACKGROUND: Respiratory syncytial virus (RSV) is the major viral cause of infant and childhood lower respiratory tract disease worldwide. Defining the optimal target product profile (TPP) is complicated due to a wide range of possible vaccine properties, modalities and an incomplete understanding of the mechanism of natural immunity. We report consensus population level impact projections based on two mathematical models applied to a low income setting. METHOD: Two structurally distinct age-specific deterministic compartmental models reflecting uncertainty associated with the natural history of infection and the mechanism by which immunity is acquired and lost were constructed...
November 28, 2016: Vaccine
https://www.readbyqxmd.com/read/27908639/animal-models-of-respiratory-syncytial-virus-infection
#2
Geraldine Taylor
Human respiratory syncytial virus (hRSV) is a major cause of respiratory disease and hospitalisation of infants, worldwide, and is also responsible for significant morbidity in adults and excess deaths in the elderly. There is no licensed hRSV vaccine or effective therapeutic agent. However, there are a growing number of hRSV vaccine candidates that have been developed targeting different populations at risk of hRSV infection. Animal models of hRSV play an important role in the preclinical testing of hRSV vaccine candidates and although many have shown efficacy in preclinical studies, few have progressed to clinical trials or they have had only limited success...
November 29, 2016: Vaccine
https://www.readbyqxmd.com/read/27903593/respiratory-syncytial-virus-infection-detection-and-new-options-for-prevention-and-treatment
#3
REVIEW
Cameron Griffiths, Steven J Drews, David J Marchant
Respiratory syncytial virus (RSV) infection is a significant cause of hospitalization of children in North America and one of the leading causes of death of infants less than 1 year of age worldwide, second only to malaria. Despite its global impact on human health, there are relatively few therapeutic options available to prevent or treat RSV infection. Paradoxically, there is a very large volume of information that is constantly being refined on RSV replication, the mechanisms of RSV-induced pathology, and community transmission...
January 2017: Clinical Microbiology Reviews
https://www.readbyqxmd.com/read/27895172/pulmonary-dendritic-cell-subsets-shape-the-respiratory-syncytial-virus-specific-cd8-t-cell-immunodominance-hierarchy-in-neonates
#4
Allison M W Malloy, Tracy J Ruckwardt, Kaitlyn M Morabito, Annie W Lau-Kilby, Barney S Graham
Young infants are generally more susceptible to viral infections and experience more severe disease than do adults. CD8(+) T cells are important for viral clearance, and although often ineffective in neonates they can be protective when adequately stimulated. Using a murine CB6F1/J hybrid model of respiratory syncytial virus (RSV) infection, we previously demonstrated that the CD8(+) T cell immunodominance hierarchy to two RSV-derived epitopes, K(d)M282-90 and D(b)M187-195, was determined by the age at infection...
November 28, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27883286/influenza-in-poland-in-2013-and-2013-2014-epidemic-season
#5
Katarzyna Kondratiuk, Mirosław P Czarkowski, Ewelina Hallmann-Szelińska1, Ewa Staszewska, Karolina Bednarska, Ewa Cielebąk, Lidia B Brydak
OBJECTIVE: Analysis of epidemiological situation of influenza in Poland in 2013 and 2013/14 epidemic season in reference to previous years and seasons. MATERIAL AND METHODS: Analysis was based on: 1) data collected within influenza routine surveillance system in Poland, including data published in annual bulletins “Infectious diseases and poisonings in Poland” as well as unpublished data gathered in the Department of Epidemiology of the NIPH-NIH; 2) data collected within influenza system - Sentinel, and beyond this system, concerning results of virological tests carried out in 2013/14 epidemic season in the Department of Influenza Research, National Influenza Center in the NIPHNIH and/or laboratories of provincial sanitary and epidemiological stations which are gathered in the National Influenza Center...
2016: Przegla̧d Epidemiologiczny
https://www.readbyqxmd.com/read/27881643/inclusion-body-fusion-of-human-parainfluenza-virus-type-3-regulated-by-acetylated-%C3%AE-tubulin-enhances-viral-replication
#6
Shengwei Zhang, Yanliang Jiang, Qi Cheng, Zhong Yi, Yali Qin, Mingzhou Chen
: Viral inclusion bodies (IBs) or replication factories are unique structures generated by viral proteins together with some cellular proteins as a platform for efficient viral replication, but little is known about the mechanism underlying IB formation and fusion. Our previous study demonstrated that the interaction between the nucleoprotein (N) and phosphoprotein (P) of human parainfluenza virus type 3 (HPIV3), an enveloped virus of great medical impact, can form IBs. In this study, we found that small IBs can fuse with each other to form large IBs that enhance viral replication...
November 23, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27856770/update-from-the-advisory-committee-on-immunization-practices
#7
Jennifer E Schuster, Sean O'Leary, David W Kimberlin
The Advisory Committee on Immunization Practices (ACIP) consists of medical and public health experts who develop recommendations on vaccine use in the United States. The ACIP meets 3 times per year, and members and Centers for Disease Control (CDC) staff present findings and discuss vaccine research, vaccine effectiveness (VE) and safety, clinical trial results, and labeling/package insert information. Outbreaks of vaccine-preventable diseases and vaccine shortages are also discussed. Nonvoting representatives from the American Academy of Pediatrics and the Pediatric Infectious Diseases Society are present...
December 2016: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/27851799/absence-of-association-between-cord-specific-antibody-levels-and-severe-respiratory-syncytial-virus-rsv-disease-in-early-infants-a-case-control-study-from-coastal-kenya
#8
Joyce Uchi Nyiro, Charles Jumba Sande, Martin Mutunga, Patience Kerubo Kiyuka, Patrick Kioo Munywoki, John Anthony G Scott, David James Nokes
BACKGROUND: The target group for severe respiratory syncytial virus (RSV) disease prevention is infants under 6 months of age. Vaccine boosting of antibody titres in pregnant mothers could protect these young infants from severe respiratory syncytial virus (RSV) associated disease. Quantifying protective levels of RSV-specific maternal antibody at birth would inform vaccine development. METHODS: A case control study nested in a birth cohort (2002-07) was conducted in Kilifi, Kenya; where 30 hospitalised cases of RSV-associated severe disease were matched to 60 controls...
2016: PloS One
https://www.readbyqxmd.com/read/27821195/characterizing-the-risk-of-respiratory-syncytial-virus-in-infants-with-older-siblings-a-population-based-birth-cohort-study
#9
P Jacoby, K Glass, H C Moore
From a population-based birth cohort of 245 249 children born in Western Australia during 1996-2005, we used linkage of laboratory and birth record datasets to obtain data including all respiratory syncytial virus (RSV) detections during infancy from a subcohort of 87 981 singleton children born in the Perth metropolitan area from 2000 to 2004. Using log binomial regression, we found that the risk of infant RSV detection increases with the number of older siblings, with those having ⩾3 older siblings experiencing almost three times the risk (relative risk 2·83, 95% confidence interval 2·46-3·26) of firstborn children...
November 8, 2016: Epidemiology and Infection
https://www.readbyqxmd.com/read/27816139/health-care-acquired-viral-respiratory-diseases
#10
REVIEW
Ryan K Dare, Thomas R Talbot
Health care-acquired viral respiratory infections are common and cause increased patient morbidity and mortality. Respiratory syncytial virus and influenza virus are frequently transmitted in the hospital setting. Studies report decreased nosocomial transmission when aggressive infection control measures are implemented with more success using a multicomponent approach. Influenza vaccination of health care personnel has been shown to further decrease rates of transmission, thus mandatory vaccination is becoming more common...
December 2016: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/27802292/clinical-and-epidemiologic-characteristics-of-hospitalized-patients-with-laboratory-confirmed-respiratory-syncytial-virus-infection-in-eastern-china-between-2009-and-2013-a-retrospective-study
#11
Dawei Cui, Luzhao Feng, Yu Chen, Shengjie Lai, Zike Zhang, Fei Yu, Shufa Zheng, Zhongjie Li, Hongjie Yu
Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality worldwide in children aged <5 years and older adults with acute lower respiratory infections (ALRIs). However, few studies regarding the epidemiology of hospitalizations for RSV infection have been performed previously in China. Here, we aimed to describe the clinical and epidemiologic characteristics of hospitalized patients with laboratory-confirmed RSV infection in eastern China. Active surveillance for hospitalized ALRI patients using a broad case definition based on symptoms was performed from 2009-2013 in 12 sentinel hospitals in eastern China...
2016: PloS One
https://www.readbyqxmd.com/read/27799521/vaccination-strategies-against-respiratory-syncytial-virus
#12
Dan Yamin, Forrest K Jones, John P DeVincenzo, Shai Gertler, Oren Kobiler, Jeffrey P Townsend, Alison P Galvani
Respiratory syncytial virus (RSV) is the most common cause of US infant hospitalization. Additionally, RSV is responsible for 10,000 deaths annually among the elderly across the United States, and accounts for nearly as many hospitalizations as influenza. Currently, several RSV vaccine candidates are under development to target different age groups. To evaluate the potential effectiveness of age-specific vaccination strategies in averting RSV incidence, we developed a transmission model that integrates data on daily infectious viral load and changes of behavior associated with RSV symptoms...
November 15, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27791117/structural-basis-for-nonneutralizing-antibody-competition-at-antigenic-site-ii-of-the-respiratory-syncytial-virus-fusion-protein
#13
Jarrod J Mousa, Marion F Sauer, Alexander M Sevy, Jessica A Finn, John T Bates, Gabriela Alvarado, Hannah G King, Leah B Loerinc, Rachel H Fong, Benjamin J Doranz, Bruno E Correia, Oleksandr Kalyuzhniy, Xiaolin Wen, Theodore S Jardetzky, William R Schief, Melanie D Ohi, Jens Meiler, James E Crowe
Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting antigenic site II of the RSV fusion (F) protein, a key target in vaccine development. There are limited reported naturally occurring human mAbs to site II; therefore, the structural basis for human antibody recognition of this major antigenic site is poorly understood...
November 1, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27771388/intranasal-treatment-with-a-novel-immunomodulator-mediates-innate-immune-protection-against-lethal-pneumonia-virus-of-mice
#14
Elisa C Martinez, Ravendra Garg, Pratima Shrivastava, Susantha Gomis, Sylvia van Drunen Littel-van den Hurk
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in infants and young children. There are no licensed RSV vaccines available, and the few treatment options for high-risk individuals are either extremely costly or cause severe side effects and toxicity. Immunomodulation mediated by a novel formulation consisting of the toll-like receptor 3 agonist poly(I:C), an innate defense regulator peptide and a polyphosphazene (P-I-P) was evaluated in the context of lethal infection with pneumonia virus of mice (PVM)...
October 19, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27764150/stability-characterization-of-a-vaccine-antigen-based-on-the-respiratory-syncytial-virus-fusion-glycoprotein
#15
Jessica A Flynn, Eberhard Durr, Ryan Swoyer, Pedro J Cejas, Melanie S Horton, Jennifer D Galli, Scott A Cosmi, Amy S Espeseth, Andrew J Bett, Lan Zhang
Infection with Respiratory Syncytial Virus (RSV) causes both upper and lower respiratory tract disease in humans, leading to significant morbidity and mortality in both young children and older adults. Currently, there is no licensed vaccine available, and therapeutic options are limited. During the infection process, the type I viral fusion (F) glycoprotein on the surface of the RSV particle rearranges from a metastable prefusion conformation to a highly stable postfusion form. In people naturally infected with RSV, most potent neutralizing antibodies are directed to the prefusion form of the F protein...
2016: PloS One
https://www.readbyqxmd.com/read/27750448/respiratory-syncytial-virus-vaccines-an-update-on-those-in-the-immediate-pipeline
#16
Susanna Esposito, Giada Di Pietro
Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development...
October 18, 2016: Future Microbiology
https://www.readbyqxmd.com/read/27746682/ginseng-the-natural-effectual-antiviral-protective-effects-of-korean-red-ginseng-against-viral-infection
#17
Kyungtaek Im, Jisu Kim, Hyeyoung Min
Korean Red Ginseng (KRG) is a heat-processed ginseng developed by the repeated steaming and air-drying of fresh ginseng. Compared with fresh ginseng, KRG has been shown to possess greater pharmacological activities and stability because of changes that occur in its chemical constituents during the steaming process. In addition to anticancer, anti-inflammatory, and immune-modulatory activities, KRG and its purified components have also been shown to possess protective effects against microbial infections. Here, we summarize the current knowledge on the properties of KRG and its components on infections with human pathogenic viruses such as respiratory syncytial virus, rhinovirus, influenza virus, human immunodeficiency virus, human herpes virus, hepatitis virus, norovirus, rotavirus, enterovirus, and coxsackievirus...
October 2016: Journal of Ginseng Research
https://www.readbyqxmd.com/read/27738052/clinical-and-socioeconomic-burden-of-respiratory-syncytial-virus-infection-in-children
#18
Terho Heikkinen, Emilia Ojala, Matti Waris
BACKGROUND:  Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on the full impact of RSV infection on outpatient children. METHODS:  We analyzed the burden of RSV illness in a prospective cohort study of children aged ≤13 years during 2 consecutive respiratory seasons in Turku, Finland (2231 child-seasons of follow-up). We examined the children and obtained nasal swabs for the detection of RSV during each respiratory illness...
October 12, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27721128/a-single-intranasal-immunization-with-a-subunit-vaccine-formulation-induces-higher-mucosal-iga-production-than-live-respiratory-syncytial-virus
#19
Ravendra Garg, Michael Theaker, Elisa C Martinez, Sylvia van Drunen Littel-van den Hurk
Respiratory syncytial virus (RSV) causes serious respiratory illness in infants and elderly. RSV infection induces short-lived immunity, which leaves people prone to re-infection. In contrast, the RSV fusion (F) protein formulated with a novel adjuvant (∆F/TriAdj) elicits long term protective immunity. A comparison of RSV-immunized mice to mice vaccinated with a single dose of ∆F/TriAdj showed no difference in IgG1 and IgG2a production; however, local IgA secreting memory B cell development and B cell IgA production were significantly lower in RSV vaccinated mice than in ∆F/TriAdj-immunized mice...
October 6, 2016: Virology
https://www.readbyqxmd.com/read/27720994/non-invasive-epicutaneous-vaccine-against-respiratory-syncytial-virus-preclinical-proof-of-concept
#20
Pierre-Louis Hervé, Delphyne Descamps, Charlotte Deloizy, Véronique Dhelft, Daphné Laubreton, Edwige Bouguyon, Abdelhak Boukadiri, Catherine Dubuquoy, Thibaut Larcher, Pierre-Henri Benhamou, Jean-François Eléouët, Nicolas Bertho, Lucie Mondoulet, Sabine Riffault
To put a Respiratory Syncytial Virus (RSV) vaccine onto the market, new vaccination strategies combining scientific and technical innovations need to be explored. Such a vaccine would also need to be adapted to the vaccination of young children that are the principal victims of acute RSV infection. In the present project, we describe the development and the preclinical evaluation of an original epicutaneous RSV vaccine that combines two technologies: Viaskin® epicutaneous patches as a delivery platform and RSV N-nanorings (N) as a subunit antigen...
October 6, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
keyword
keyword
105383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"